Indonesia Regulatory Issues
Indonesia Regulatory Issues
$2,995.00
Challenges for foreign pharma companies in relation to Indonesia’s pharma system include lengthy and variable approval periods, compulsory licenses, and counterfeits.
Publisher: Datamonitor Healthcare
- Description
- Contents
- Samples
Challenges for foreign pharma companies in relation to Indonesia’s pharma system include lengthy and variable approval periods, compulsory licenses, and counterfeits. Furthermore, drug companies are not allowed to have a foreign investment level of more than 75%.
Table of Contents
4 EXECUTIVE SUMMARY
4 Key findings
5 DRUG APPROVALS
6 LABELING
7 DISTRIBUTION
8 FOREIGN DIRECT INVESTMENT
9 INTELLECTUAL PROPERTY ENVIRONMENT
9 Compulsory licensing
10 Counterfeiting
12 BIBLIOGRAPHY
List of Tables
9 Table 1: Indonesia: Compulsory licenses issued in September 2012
Table 1: Indonesia: Compulsory licenses issued in September 2012
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Indonesia Healthcare System Overview 
Sign up to the